A Study to Investigate Mocertatug Rezetecan as Maintenance Treatment for Participants With MMRp Endometrial Cancer (BEHOLD-Endometrial02)

The purpose of this study is to see how well mocertatug rezetecan (Mo-Rez) in combination with physician's choice of immunotherapy (dostarlimab or pembrolizumab) works as maintenance therapy in participants with advanced or recurrent endometrial cancer (EC) compared with the physician's choice of immunotherapy (dostarlimab or pembrolizumab) alone, which represents the current standard of care. The study will also assess whether the drug combination is safe and tolerated well by participants compared to standard of care and will help us better understand its impact on Health-Related Quality of

Trial Details

NCT ID
NCT07684599
Phase
PHASE3
Sponsor
GlaxoSmithKline
Status
RECRUITING
Cancer Type
Uterine Cancer
Interventions
  • Mocertatug rezetecan
  • Dostarlimab
  • Pembrolizumab
Locations (sample)
  • Toronto, Ontario, Canada|43.65333,-79.38389
  • Montreal, Quebec, Canada|45.50884,-73.58781
  • Fukuoka, Japan|33.6,130.41667
  • Fukushima, Japan|37.75,140.46667
  • Hokkaido, Japan

Key Eligibility Criteria

  • Is at least 18 years of age and the legal age of consent in the jurisdiction in which the study is taking place at the time of signing the Informed…
  • Has received 6 cycles of first-line therapy (i.e. induction therapy), consisting of platinum-based doublet chemotherapy (e.g., carboplatin/paclitax…
  • Is able to commence C1D1 of study treatment within 3 - 9 weeks of the final dose of first-line therapy.
  • Is deemed suitable to continue with maintenance therapy with immune checkpoint inhibition (dostarlimab or pembrolizumab).

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Uterine Cancer Trials on Trialify →